Johnson & Johnson’s Janssen Pharmaceutical disclosed earlier that following a review of its portfolio and an assessment of the respiratory syncytial virus vaccine landscape, it will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study. "The decision to discontinue the Company’s RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development investments to focus on medicines with the greatest potential benefit to patients. The Company remains committed to investing in internal discovery, development and external innovation across its Therapeutic Areas," the company said in a statement.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson assumed with a Neutral at UBS
- STAAR Surgical names Warren Foust COO, Magda Michna, as chief of medical affairs
- Johnson & Johnson initiated with a Neutral at UBS
- Johnson & Johnson issues statement on Third Circuit review petition
- Johnson & Johnson put volume heavy and directionally bearish
